中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.015 seconds)

    FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR MONITORING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE
    1.
    发明申请
    FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR MONITORING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE 审中-公开
    FECAL LACTOFERRIN作为用于确定疾病严重程度的生物标记物和用于监测患有CLOSTRIDIUM DIFFICILE病的患者的感染

    公开(公告)号：US20120276059A1

    公开(公告)日：2012-11-01

    申请号：US13457049

    申请日：2012-04-26

    Applicant: JAMES HUNTER BOONE ,  DAVID M. LYERLY ,  TRACY D. WILKINS ,  ROBERT J. CARMAN

    Inventor： JAMES HUNTER BOONE ,  DAVID M. LYERLY ,  TRACY D. WILKINS ,  ROBERT J. CARMAN

    IPC: G01N33/569 ,  C12Q1/18 ,  A61K31/4164 ,  A61K38/16 ,  A61K35/74 ,  G01N33/573 ,  C12Q1/68

    CPC classification number: G01N33/56911 ,  A61K31/4164 ,  A61K31/7034 ,  A61K35/74 ,  A61K38/14 ,  A61K45/06 ,  G01N2333/33 ,  G01N2333/79 ,  G01N2800/52 ,  G01N2800/56

    Abstract: Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence of C. difficile disease is detected using a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected of C. difficile disease, if GDH is detected indicating the presence of C. difficile, and then toxins A and/or B are detected to indicate toxigenic C. difficile and support a diagnosis of C. difficile-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation.

    Abstract translation: 艰难梭菌病涉及一系列临床表现，从轻度到自限性腹泻到威胁生命的假膜性结肠炎和巨结肠。 艰难梭菌的病例根据疾病的严重程度不同地进行治疗。 轻度和中度病例可用甲硝唑治疗，而中重度和复发病例通常用万古霉素或fidaxomicin治疗。 使用包括艰难梭菌抗原（GDH），毒素A和B以及粪便乳铁蛋白的生物标志物组检测艰难梭菌病的存在。 在疑似艰难梭菌病的患者中，如果检测到GDH，表明存在艰难梭菌，然后检测到毒素A和/或B，以表明产毒性艰难梭菌，并支持艰难梭菌相关疾病，粪便 通过指示肠道炎症的量来测量乳铁蛋白浓度以确定疾病的严重性。

    ANIMAL DETERRENT FOR PROTECTING PLANTS
    2.
    发明申请
    ANIMAL DETERRENT FOR PROTECTING PLANTS 失效
    动物保护植物检疫

    公开(公告)号：US20090252776A1

    公开(公告)日：2009-10-08

    申请号：US12484055

    申请日：2009-06-12

    Applicant: Tracy D WILKINS

    Inventor： Tracy D WILKINS

    IPC: A01N25/12 ,  A01P17/00

    CPC classification number: A01N59/00 ,  A01N25/00 ,  A01N25/10 ,  A01N2300/00

    Abstract: The invention provides materials, compositions, methods, and kits for deterring or repelling animals from eating plant materials. The invention relates to the use of particulate matter to deter animals from eating plant materials that are susceptible to grazing by animals. In exemplary embodiments, an adhesive is applied to target plant material and the particulate matter is then applied prior to curing or drying of the adhesive.

    Abstract translation: 本发明提供用于阻止或排斥动物吃植物材料的材料，组合物，方法和试剂盒。 本发明涉及使用颗粒物质来阻止动物吃动物易受放牧的植物材料。 在示例性实施例中，将粘合剂施加到靶植物材料上，然后在固化或干燥粘合剂之前施加颗粒物质。

    Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors
    4.
    发明授权
    Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors 失效
    检测，分离和纯化艰难梭菌毒素A及其受体的方法

    公开(公告)号：US4863852A

    公开(公告)日：1989-09-05

    申请号：US828404

    申请日：1986-02-11

    Applicant: Tracy D. Wilkins ,  Howard C. Krivan

    Inventor： Tracy D. Wilkins ,  Howard C. Krivan

    IPC: G01N33/569

    CPC classification number: G01N33/56911 ,  Y10S435/803 ,  Y10S435/842 ,  Y10S436/829 ,  Y10S530/825

    Abstract: A method is provided for detecting the presence of C. difficile toxin A. Stool or other appropriate specimen is contacted with a reagent containing an available non-reducing galactose-alpha-1-3-galactosyl structure, which is a specific receptor for toxin A. The reagent may be intact cells, cell membranes, membrane fractions containing the toxin A receptor structure, glycoconjugates, as well as the purified toxin A receptor per se. Binding of toxin A is determined by conventional assay techniques. The method may also be used to isolate and purify toxin A. Conversely, immobilized toxin A is used to detect, isolate, or purify biological materials of interest containing the receptor structure.

    Abstract translation: 提供了一种用于检测艰难梭菌毒素A的存在的方法A.将粪便或其它合适的标本与含有可用的非还原性半乳糖-α-1-3-半乳糖结构的试剂接触，所述非还原性半乳糖-α-1-3-半乳糖结构是毒素A的特异性受体 试剂可以是完整的细胞，细胞膜，含有毒素A受体结构的膜级分，糖缀合物，以及纯化的毒素A受体本身。 通过常规测定技术测定毒素A的结合。 该方法也可用于分离和纯化毒素A.相反，固定毒素A用于检测，分离或纯化包含受体结构的感兴趣的生物材料。

    Animal deterrent for protecting plants
    9.
    发明授权
    Animal deterrent for protecting plants 失效
    用于保护植物的动物威慑

    公开(公告)号：US08431144B2

    公开(公告)日：2013-04-30

    申请号：US12484055

    申请日：2009-06-12

    Applicant: Tracy D. Wilkins

    Inventor： Tracy D. Wilkins

    IPC: A01N25/24 ,  A01N25/00 ,  A61K9/14 ,  A61K33/00

    CPC classification number: A01N59/00 ,  A01N25/00 ,  A01N25/10 ,  A01N2300/00

    Abstract: The invention provides materials, compositions, methods, and kits for deterring or repelling animals from eating plant materials. The invention relates to the use of particulate matter to deter animals from eating plant materials that are susceptible to grazing by animals. In exemplary embodiments, an adhesive is applied to target plant material and the particulate matter is then applied prior to curing or drying of the adhesive.

    Abstract translation: 本发明提供用于阻止或排斥动物吃植物材料的材料，组合物，方法和试剂盒。 本发明涉及使用颗粒物质来阻止动物吃动物易受放牧的植物材料。 在示例性实施例中，将粘合剂施加到靶植物材料上，然后在固化或干燥粘合剂之前施加颗粒物质。

    FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR TREATING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE
    10.
    发明申请
    FECAL LACTOFERRIN AS A BIOMARKER FOR DETERMINING DISEASE SEVERITY AND FOR TREATING INFECTION IN PATIENTS WITH CLOSTRIDIUM DIFFICILE DISEASE 审中-公开
    FECAL LACTOFERRIN作为用于确定疾病严重程度的生物标记物和用于治疗患有CLOSTRIDIUM DIFFICILE病的患者的感染

    公开(公告)号：US20120276060A1

    公开(公告)日：2012-11-01

    申请号：US13457064

    申请日：2012-04-26

    Applicant: JAMES HUNTER BOONE ,  DAVID M. LYERLY ,  TRACY D. WILKINS ,  ROBERT J. CARMAN

    Inventor： JAMES HUNTER BOONE ,  DAVID M. LYERLY ,  TRACY D. WILKINS ,  ROBERT J. CARMAN

    IPC: G01N33/569 ,  A61K35/74 ,  A61K38/16 ,  A61K31/4164

    CPC classification number: G01N33/56911 ,  A61K31/4164 ,  A61K31/7034 ,  A61K35/74 ,  A61K38/14 ,  A61K45/06 ,  G01N2333/33 ,  G01N2333/79 ,  G01N2800/52 ,  G01N2800/56

    Abstract: Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence of C. difficile disease is detected using a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected of C. difficile disease, if GDH is detected indicating the presence of C. difficile, and then toxins A and/or B are detected to indicate toxigenic C. difficile and support a diagnosis of C. difficile-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation.

    Abstract translation: 艰难梭菌病涉及一系列临床表现，从轻度到自限性腹泻到威胁生命的假膜性结肠炎和巨结肠。 艰难梭菌的病例根据疾病的严重程度不同地进行治疗。 轻度和中度病例可用甲硝唑治疗，而中重度和复发病例通常用万古霉素或fidaxomicin治疗。 使用包括艰难梭菌抗原（GDH），毒素A和B以及粪便乳铁蛋白的生物标志物组检测艰难梭菌病的存在。 在疑似艰难梭菌病的患者中，如果检测到GDH，表明存在艰难梭菌，然后检测到毒素A和/或B，以表明产毒性艰难梭菌，并支持艰难梭菌相关疾病，粪便 通过指示肠道炎症的量来测量乳铁蛋白浓度以确定疾病的严重性。

Patent Agency Ranking